Fourth quarter and full year 2023 results

Fourth quarter and full year 2023 results were reviewed by management during a live audio webcast with the financial community on February 1st, 2024. The presentation was followed by a Q&A session.

14:30 - 16:00 CET (8:30am – 10am EST)

Featuring

Paul Hudson

Paul Hudson

Chief Executive Officer

Jean-Baptiste de Chatillon

Jean-Baptiste de Chatillon

Chief Financial Officer

Brian Foard

Brian Foard

Specialty Care

Olivier Charmeil

Olivier Charmeil

General Medicines

Houman Ashrafian

Houman Ashrafian

Head of Research and Development

Thomas Triomphe

Thomas Triomphe

Vaccines

Julie van Ongevalle

Julie van Ongevalle

Consumer Healthcare

Roy Papatheodorou

Roy Papatheodorou

General Counsel

Highlights

Paul Hudson comments on 2023 results

Full-Year 2023 results and R&D highlights

2023 was a turning-point year for Sanofi, paving the way for our scientific leadership in Immunology. Coupled with our AI at-scale ambitions, we go forward as a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth.
Paul Hudson

Paul Hudson

Chief Executive Officer

Fourth quarter and full year 2023 results

Downloads

Presentation

Press release

Q4 and FY 2023 Income statements, cash flow statements, balance sheet

Q4 and FY 2023 net sales by GBU, franchise, geographic region and product

R&D appendix

Q4 2023 Memorandum for modelling purposes

Infographic

Infographic (accessible version)

Contact

Investor Relations

investor.relations@sanofi.com

More contact information